Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Drug Pricing topic
No spam. Unsubscribe anytime.
Senate committee hears wide-ranging testimony on proposal to create Prescription Drug Affordability Board, defers vote
Summary
Chairman Talbot's SB 401 would create a state Prescription Drug Affordability Board to collect confidential drug-price data and produce an annual report; supporters said transparency is essential, while senators pressed on legal risks and whether manufacturers might pull products. The committee deferred the bill for further hearings next week.
Chairman Talbot introduced Senate Bill 401 on March 25, 2026, proposing a Prescription Drug Affordability Board to gather confidential price and cost data from drug manufacturers, require price-related disclosures in certain marketing to health-care providers, and produce an annual report to the Legislature.
The bill, Talbot said, would not itself set drug prices. "This board does not set prices," he told the committee, saying the panel's role would be transparency and analysis and that any recommendation on pricing limits would be up to lawmakers. Talbot said the board would be housed in the Department of Insurance, composed of public-health and industry experts, and would have enforcement mechanisms tied to the state's unfair trade practices law.
Jason Young, cofounder of Americans for Lower Drug Prices, testified in favor and framed the proposal as a first step to understanding why medicines cost so much. "You can't fix what you can't see," Young told the committee, urging officials to require manufacturers to report costs, research-and-development spending and related data so Louisiana could trace where money flows in the drug supply chain. Young said transparency would let the state identify policy choices and better manage Medicaid and other public spending.
Lawmakers pressed Young and Talbot on several points. Senator Foyle asked whether a state board that later recommended pricing limits could prompt manufacturers to stop selling in Louisiana; Young replied that other developed nations and several U.S. states have taken similar steps without companies exiting the market. Senators also questioned whether previous state boards had been retired and why; Young and Talbot said some PDABs were paused for budgetary housekeeping while others remain active and that the proposed Louisiana board is narrowly focused on reporting and confidentiality.
Committee members also pressed on operational details: the proposed board would have nine members (agency designees, pharmacy representation and legislative appointees), meet quarterly and report to the Legislature at least 60 days before the regular session. Talbot said the goal was to have usable information for lawmakers, not a predetermined outcome: "This isn't I'm doing this board so drug prices have to go down 30%. This is let's just gather all the data," he said.
Supporters including Louisiana Progress and other local organizations described the measure as an evidence-gathering step. After extended testimony and questioning, Talbot withdrew the bill for the day and said he would return it to the calendar for a fuller PBM/drug-pricing week next Wednesday.
The committee did not take a final vote on SB 401 during this session; Talbot said he planned additional hearings with interested parties present.
What happens next: SB 401 will be placed on the committee's schedule for a future meeting (next Wednesday, per the chair) for more testimony and debate before any committee vote.
